Nerites (Madison, WI) a development stage company foced on tissue repair products and coatings for medical device coatings closed a $5.7M series A financing. Participants include Venture Investors and Black Mountain Ventures.

Accumetrics (San Diego, CA) develops diagnostic tests for measurement of anti-platelet drug response closed a $28.8M Series D financing, Participants include Arnerich Massena & Associates, BBT Fund, Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures.

Affimed  (Germany) developer of recombinant antibody therapeutics had a second closing of an additional $7.8M Series B financing from Novo Nordisk bringing the total round to $47.2M. Earlier participants include BioMedInvest, OrbiMed Advisors, Life Sciences Partners and FirstVentury.

Ocera Therapeutics (San Diego, CA) a clinical stage company focused on gastrointestinal and liver diseases closed a $35.5M Series C financing. Participants include Montagu Newhall Associates, InterWest Partners, AgeChem Venture Fund, Cross Creek Capital, FinTech, CDIB BioScience, Domain Associates, Sofinnova Ventures and Thomas, McNerney & Partners.

GraftCath (Coon Rapids, MN) a commercialization stage medical device company focused on reducing infections for dialysis patients closed a $11.8M Series D financing. Participants include Affinity Capital Management, Ascension Health Ventures, Cutlass Capital, Sapient Capital and Three Arch Partners.

Ranier Technology (United Kingdom) a development stage company focused on artificial spinal disc replacement closed a $15.8M Series C financing. Participants include Alliance Trust Equity Partners and First Ventures.

Q Therapeutics (Salt Lake City, UT) a development-stage company focused on stem cell therapies for CNS-related disease closed the first tranche of a $15M Series B financing. Participants include vSpring Capital, Invitrogen, Epic Ventures, Toucan Capital, University of Utah Research Foundation, Salt Lake Life Science Angels and Q management.

Atlas Genetics (England) developer of point-of-care molecular diagnostics for bacterial and viral disease closed a $4.1M Series A financing. Participants include South West Ventures Fund and Finance South Wales Growth Fund.

Moksha8 (San Francisco, CA) a diversified commercialization stage company focused on delivery of products to emerging markets closed a combo $15M Series B financing and Series A (see below). Participants include TPG Biotech, Votorantim and Lit Tele.

Moksha8 (San Francisco, CA) a diversified commercialization stage company focused on delivery of products to emerging markets closed a combo $24M Series A financing and Series B (see above). Participants include TPG Biotech.